ArticleBBA advances2026
Inhibitors of phosphodiesterase 1 enhance paclitaxel cytotoxicity in a MDA-MB-231-derived cell line by promoting microtubule stabilization.
Article in BBA advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance of tumor cells to chemotherapy remains a critical obstacle to effective cancer treatment. Although paclitaxel is one of the most commonly used chemotherapeutic agents for treating triple-negative breast cancer (TNBC), the mechanisms underlying paclitaxel resistance are not fully understood. We previously found that phosphodiesterase 1C (PDE1C) was substantially upregulated in a paclitaxel-resistant T50RN cell clone established from the human TNBC cell line MDA-MD-231. In this study, we aimed to explore whether and how PDE1C modulates resistance to paclitaxel in T50RN cells. Our results showed that depletion of PDE1C enhanced paclitaxel cytotoxicity, and that pharmacological inhibition of PDE1 potentiated paclitaxel-induced antiproliferative and antimitotic effects in T50RN cells. Additionally, intracellular cyclic adenosine monophosphate (cAMP) levels were lower in T50RN cells than in parental MDA-MB-231 cells. PDE1 inhibition restored the cAMP level, suggesting that cAMP-degrading activity of PDE1 is elevated in the T50RN cells. Similar to PDE1 inhibitors, the cell permeable cAMP analog 8‑bromo-cAMP or the adenylate cyclase activator forskolin increased cAMP levels and concurrently augmented paclitaxel-induced cytotoxicity and spindle abnormalities in T50RN cells. Furthermore, PDE1 inhibitors, forskolin, and an agonist of the cAMP downstream effector EPAC enhanced paclitaxel-mediated microtubule (MT) stabilization. Thus, PDE1 inhibition may act through cAMP/EPAC signaling to facilitate MT stabilization and potentiate the antiproliferative and antimitotic effects of paclitaxel in T50RN cells. Upon PDE1 inhibition, paclitaxel-treated T50RN cells exhibited signs of endoplasmic reticulum (ER) stress and apoptosis. Together, our
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.